RenovoRx, Inc.
RNXT· Nasdaq
Released Aug 14, 2025, after the close
10-Q filed Aug 14, 2025, 45 days after period end · 0001641172-25-024020
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $422.00K | — | — | — |
| Net Income | -$2.90M | -$2.39M | -$2.33M | -$2.59M |
| EPS Diluted |
RenovoRx, Inc. · CIK 1574094 · Engraved from SEC EDGAR
| -$0.08 |
| -$0.10 |
| -$0.22 |
| -$0.29 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.